Harold Foster, MD
Surgery · Opelika, ALNPI 1811925738
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (52.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 87.9% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $4,764 and has fallen 72.3% since, to $1,318 in 2025.
Across 118 payments — averaging $96.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$10K
- Lucid Diagnostics Inc.$261
- AbbVie$183
- Johnson & Johnson$114
- Endomagnetics Ltd$114
- TELA Bio, Inc.$76
- plus $636 from 23 others
What the payments were for
- Speaking & faculty fees$1,50013%
- Travel & lodging$9488%
- Food & beverage$2,95626%
- Education$6,00053%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 59 | $10,021 |
| Lucid Diagnostics Inc. | 3 | $261 |
| AbbVie(2 entities) | 10 | $183 |
| Johnson & Johnson(2 entities) | 8 | $114 |
| Endomagnetics Ltd | 2 | $114 |
| TELA Bio, Inc. | 4 | $76 |
| Davol Inc. | 3 | $72 |
| Angiodynamics, Inc. | 2 | $60 |
| W. L. Gore & Associates, Inc. | 3 | $53 |
| Conmed Corporation | 2 | $52 |
| Baxter Healthcare | 1 | $38 |
| Ossur Americas, Inc. | 2 | $35 |
| Cook Medical LLC | 2 | $32 |
| Smith+Nephew | 2 | $31 |
| KCI USA, Inc. | 1 | $26 |
| Integra Lifesciences Corporation | 1 | $25 |
| Ardelyx, Inc. | 1 | $23 |
| Merck | 1 | $23 |
| Kerecis Limited | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $19 |
| Cardinal Health 414 LLC | 1 | $18 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $17 |
| Acera Surgical, Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Bard Peripheral Vascular, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Focal Therapeutics, Inc. | 1 | $13 |
| Urgo Medical North America, LLC | 1 | $13 |
| THD America, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$8,889
- Magseed$100
- Magtrace$100
How this compares
$11,404 in reported general payments places this provider in the 85th percentile of 382 surgery providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 13 | $7,510 |
| LinzessLinaclotide | 12 | $6,318 |
| CreonLipase/Protease/Amylase | 12 | $4,257 |
| Balsalazide Disodium | 15 | $4,159 |
| Pantoprazole Sodium | 124 | $1,386 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 120 | $675 |
| Esomeprazole Magnesium | 15 | $426 |
| Omeprazole | 33 | $373 |
| Sucralfate | 11 | $208 |
| Famotidine | 13 | $118 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $183 | $10,57524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 382 surgery providers in Alabama.
Other surgery in Opelika
- Allen LazenbyOpelika$17K
- John PorterfieldBessemer$972K
- Barton WoodAlabaster$702K
- Forrest RingoldMobile$678K
- Dennis FernandezHuntsville$266K
- Cameron AskewBirmingham$236K
- Terry TreadwellMontgomery$127K
- Charles NewmanGadsden$123K
- Jason BeaverDothan$106K
- John TouliatosBirmingham$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.